On March 29, AI-driven pharmaceutical company Insilico Medicine (3696.HK) announced a drug discovery collaboration with Eli Lilly, leveraging its AI engine to accelerate the discovery and development of novel therapies across multiple therapeutic areas. Under the agreement, Eli Lilly will obtain an exclusive global license for a novel oral drug targeting specific indications, currently in preclinical development, for subsequent development, production, and commercialization. Insilico Medicine will receive an upfront payment of US$115 million, with further payments contingent upon achieving development, regulatory, and commercialization milestones, bringing the total potential deal value to approximately US$2.75 billion. Additionally, the two parties will engage in multiple R&D collaborations centered around targets selected by Eli Lilly to jointly accelerate the discovery of innovative drug candidates.